Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component.
Thibault B, Ramos-Delgado F, Pons-Tostivint E, Therville N, Cintas C, Arcucci S, Cassant-Sourdy S, Reyes-Castellanos G, Tosolini M, Villard AV, Cayron C, Baer R, Bertrand-Michel J, Pagan D, Ferreira Da Mota D, Yan H, Falcomatà C, Muscari F, Bournet B, Delord JP, Aksoy E, Carrier A, Cordelier P, Saur D, Basset C, Guillermet-Guibert J. Thibault B, et al. EMBO Mol Med. 2021 Jul 7;13(7):e13502. doi: 10.15252/emmm.202013502. Epub 2021 May 25. EMBO Mol Med. 2021. PMID: 34033220 Free PMC article.
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Cancer Immunol Immunother. 2023 Jun;72(6):1891-1892. doi: 10.1007/s00262-023-03405-7. Cancer Immunol Immunother. 2023. PMID: 36847863 Free PMC article. No abstract available.
Targeting PI3K Signaling in Combination Cancer Therapy.
Pons-Tostivint E, Thibault B, Guillermet-Guibert J. Pons-Tostivint E, et al. Trends Cancer. 2017 Jun;3(6):454-469. doi: 10.1016/j.trecan.2017.04.002. Epub 2017 May 14. Trends Cancer. 2017. PMID: 28718419 Review.
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouzid E, Even C. Saleh K, et al. Eur J Cancer. 2019 Nov;121:123-129. doi: 10.1016/j.ejca.2019.08.026. Epub 2019 Sep 28. Eur J Cancer. 2019. PMID: 31574417
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Bureau M, Chatellier T, Perennec T, Goronflot T, Greilsamer C, Chene AL, Affi R, Frampas E, Bennouna J, Pons-Tostivint E. Bureau M, et al. Cancer Immunol Immunother. 2022 Jul;71(7):1747-1756. doi: 10.1007/s00262-021-03108-x. Epub 2021 Nov 28. Cancer Immunol Immunother. 2022. PMID: 34839373 Free PMC article.
43 results